Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidance clarifies beverage/supplement distinction

This article was originally published in The Tan Sheet

Executive Summary

FDA is concerned some of the novel ingredients added to conventional beverages may adulterate the products if the substances are not generally recognized as safe for those intended uses or appear at higher levels than traditional in the food supply. In a Dec. 3 draft guidance, the agency says firms may attempt to circumvent the GRAS standard for ingredients by including them in products labeled as supplements, but such products are not supplements if they are packaged as foods or use conventional food terms including "drink," "water" or "juice." While the 1guidance, "Factors that Distinguish Liquid Dietary Supplements from Beverages, Considerations Regarding Novel Ingredients, and Labeling for Beverages and Other Conventional Foods," likely is aimed at clarifying rules for energy drinks, many of which are marketed as supplements, attorney Marc Ullman said the guidance could have a "pretty broad impact" on other liquid supplement products

You may also be interested in...



FDA Supplement Beverage Guidance May Open Can Of Regulatory Worms

An FDA draft guidance has the potential to make defining a beverage as a dietary supplement much tougher

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel